Gene therapy for Parkinson's disease: where are we now and where are we going? (Q37810994)

23 August 2017

Gene therapy for Parkinson's disease: where are we now and where are we going? (English)

1 reference

23 August 2017

0 references

1 reference

Michael Jeffrey Aminoff

series ordinal

3

object named as

Michael J Aminoff

1 reference

23 August 2017

John Forsayeth

1

1 reference

PubMed ID

21091315

23 August 2017

Krystof S Bankiewicz

series ordinal

2

1 reference

23 August 2017

1 December 2010

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

23 August 2017

1 reference

23 August 2017

10

1 reference

23 August 2017

12

1 reference

23 August 2017

1839-1845

1 reference

Reservations Concerning Gene Therapy

23 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Gene therapy systems: the need, experimental approach, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

DNA and gene therapy: transfer of mouse DNA to human and mouse embryonic cells by polyoma pseudovirions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Prospects of gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Gene therapy for human genetic disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Ethics of sham surgery: perspective of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Volunteering for early phase gene transfer research in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Long term understanding of study information in research participants with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

21 January 2018

Deep brain stimulation

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Zolpidem modulates GABA(A) receptor function in subthalamic nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Subthalamic GAD gene therapy in a Parkinson's disease rat model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Synaptic and vesicular coexistence of VGLUT and VGAT in selected excitatory and inhibitory synapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Differential subcellular and subsynaptic distribution of GABA(A) and GABA(B) receptors in the monkey subthalamic nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Two genes encode distinct glutamate decarboxylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Eight years of clinical improvement in MPTP-lesioned primates after gene therapy with AAV2-hAADC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

6-[18F]fluoro-L-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Evaluation of dopaminergic presynaptic integrity: 6-[18F]fluoro-L-dopa versus 6-[18F]fluoro-L-m-tyrosine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

The GDNF family ligands and receptors - implications for neural development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Differential effects of glial cell line-derived neurotrophic factor and neurturin on developing and adult substantia nigra dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Current status of gene therapy trials for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Functional effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in parkinsonian rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Clinically relevant effects of convection-enhanced delivery of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Transduction of nonhuman primate brain with adeno-associated virus serotype 1: vector trafficking and immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

The "perivascular pump" driven by arterial pulsation is a powerful mechanism for the distribution of therapeutic molecules within the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

AAV vector-mediated correction of brain pathology in a mouse model of Niemann-Pick A disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Transient demyelination increases the efficiency of retrograde AAV transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Basic fibroblast growth factor enhances transduction, distribution, and axonal transport of adeno-associated virus type 2 vector in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Efficient gene therapy-based method for the delivery of therapeutics to primate cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Real-time MR imaging of adeno-associated viral vector delivery to the primate brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

Cannula placement for effective convection-enhanced delivery in the nonhuman primate thalamus and brainstem: implications for clinical delivery of therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERN.10.161

21 January 2018

Identifiers

DOI

10.1586/ERN.10.161

1 reference

release_2wp2dp2cd5c5bhah25gljhsvqu

23 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2wp2dp2cd5c5bhah25gljhsvqu

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

21091315

1 reference

PubMed ID

21091315